Interlaboratory evaluation of LC-MS-based biomarker assays
Validation of biomarker assays is crucial for effective drug development and clinical applications. Interlaboratory reproducibility is vital for reliable comparison and combination of data from different centers. This review summarizes interlaboratory studies of quantitative LC-MS-based biomarker assays using reference standards for calibration curves. The following points are discussed: trends in reports, reference and internal standards, evaluation of analytical validation parameters, study sample analysis and normalization of biomarker assay data. Full evaluation of these parameters in interlaboratory studies is limited, necessitating further research. Some reports suggest methods to address variations in biomarker assay data among laboratories, facilitating organized studies and data combination. Method validation across laboratories is crucial for reducing interlaboratory differences and reflecting target biomarker responses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Bioanalysis - 16(2024), 6 vom: 23. März, Seite 389-402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saito, Kosuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker assay |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36823567X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36823567X | ||
| 003 | DE-627 | ||
| 005 | 20240311232248.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1323.xml |
| 035 | |a (DE-627)NLM36823567X | ||
| 035 | |a (NLM)38334082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saito, Kosuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Interlaboratory evaluation of LC-MS-based biomarker assays |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 11.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Validation of biomarker assays is crucial for effective drug development and clinical applications. Interlaboratory reproducibility is vital for reliable comparison and combination of data from different centers. This review summarizes interlaboratory studies of quantitative LC-MS-based biomarker assays using reference standards for calibration curves. The following points are discussed: trends in reports, reference and internal standards, evaluation of analytical validation parameters, study sample analysis and normalization of biomarker assay data. Full evaluation of these parameters in interlaboratory studies is limited, necessitating further research. Some reports suggest methods to address variations in biomarker assay data among laboratories, facilitating organized studies and data combination. Method validation across laboratories is crucial for reducing interlaboratory differences and reflecting target biomarker responses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a LC–MS | |
| 650 | 4 | |a biomarker assay | |
| 650 | 4 | |a calibration curve | |
| 650 | 4 | |a interlaboratory differences | |
| 650 | 4 | |a validation | |
| 700 | 1 | |a Goda, Ryoya |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Asahina, Kota |e verfasserin |4 aut | |
| 700 | 1 | |a Kawabata, Mitsuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Uchiyama, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Andou, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Hisao |e verfasserin |4 aut | |
| 700 | 1 | |a Takahara, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Kakehi, Masaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yamauchi, Saki |e verfasserin |4 aut | |
| 700 | 1 | |a Nitta, Shin-Ichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Suga, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Hisashi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Rika |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Yoshiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 16(2024), 6 vom: 23. März, Seite 389-402 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:6 |g day:23 |g month:03 |g pages:389-402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 6 |b 23 |c 03 |h 389-402 | ||